Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96G97
UPID:
BSCL2_HUMAN
Alternative names:
Bernardinelli-Seip congenital lipodystrophy type 2 protein
Alternative UPACC:
Q96G97; G3XAE4; Q567S1; Q96SV1; Q9BSQ0
Background:
Seipin, known as Bernardinelli-Seip congenital lipodystrophy type 2 protein, is pivotal in lipid droplet formation and energy homeostasis. It orchestrates the growth of nascent lipid droplets in the endoplasmic reticulum and is essential for adipocyte differentiation and development.
Therapeutic significance:
Seipin's dysfunction is linked to severe metabolic disorders, including Congenital generalized lipodystrophy 2, Spastic paraplegia 17, and progressive encephalopathy. Understanding Seipin's role could unveil novel therapeutic strategies for these conditions.